Y-mAbs Therapeutics Inc. (YMAB)
| Bid | 5 |
| Market Cap | 232.68M |
| Revenue (ttm) | 84.86M |
| Net Income (ttm) | -23.95M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -9.62 |
| Forward PE | -11.65 |
| Analyst | Buy |
| Ask | 6.18 |
| Volume | 327,406 |
| Avg. Volume (20D) | 439,541 |
| Open | 5.53 |
| Previous Close | 5.56 |
| Day's Range | 5.14 - 5.60 |
| 52-Week Range | 5.14 - 19.12 |
| Beta | 0.67 |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...
Analyst Forecast
According to 10 analyst ratings, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 342.73% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical TrialsYMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for ass...